

Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]

Zhou X, Tao H, Shi KH. *Drug Des Devel Ther.* 2018;12:1–8.

The Editor and Publisher of *Drug Design, Development and Therapy* wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 5 with the same images from other unrelated articles. Specifically,

- Figure 5B, Liver appears to have been duplicated with the same image from Figure 4Bb from Li & Gong, 2016 (<https://doi.org/10.2147/DDDT.S113670>).
- Figure 5C, Liver appears to have been duplicated with the same image from Figure 4Bc from Li & Gong, 2016 (<https://doi.org/10.2147/DDDT.S113670>).
- Figure 5B, Spleen appears to have been duplicated with the same image from Figure 7A, Liver from Li & Wang, 2017 (<https://doi.org/10.2147/IJN.S136378>).
- Figure 5C, Spleen appears to have been duplicated with the same image from Figure 7B, Liver from Li & Wang, 2017 (<https://doi.org/10.2147/IJN.S136378>).

The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.